Indaptus Therapeutics, Inc. (INDP)

NASDAQ: INDP · IEX Real-Time Price · USD
1.860
-0.040 (-2.11%)
Feb 27, 2024, 12:09 PM EST - Market open
-2.11%
Market Cap 16.13M
Revenue (ttm) n/a
Net Income (ttm) -15.08M
Shares Out 8.40M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,364
Open 1.900
Previous Close 1.900
Day's Range 1.810 - 1.900
52-Week Range 1.500 - 4.080
Beta 1.04
Analysts Strong Buy
Price Target 12.00 (+545.16%)
Earnings Date Mar 15, 2024

About INDP

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in Au... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 6
Stock Exchange NASDAQ
Ticker Symbol INDP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for INDP stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(545.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments,...

19 days ago - GlobeNewsWire

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza Patent will provide additional protection covering a compositi...

7 weeks ago - GlobeNewsWire

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 an...

4 months ago - GlobeNewsWire

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4 , 2023

4 months ago - GlobeNewsWire

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler will present at Tribe Public's Webinar Presentation and Q&A Event ...

5 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. ...

6 months ago - GlobeNewsWire

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and pr...

7 months ago - GlobeNewsWire

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced completion of the first cohort of patients who received a single do...

7 months ago - GlobeNewsWire

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announce...

7 months ago - GlobeNewsWire

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment...

10 months ago - GlobeNewsWire

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today ann...

10 months ago - GlobeNewsWire

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Dr. Newman also to give two presentations on the Company's Decoy platform at the event to be held in Boston May 9-11, 2023 Dr. Newman also to give two presentations on the Company's Decoy platform at ...

10 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today a...

11 months ago - GlobeNewsWire

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in...

11 months ago - GlobeNewsWire

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in...

11 months ago - GlobeNewsWire

Indaptus Therapeutics to Present at the Investor Summit Conference

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today a...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of ...

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative thera...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative thera...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

First Dose Initial Side-Effect Profile Consistent with Expected Outcome First Dose Initial Side-Effect Profile Consistent with Expected Outcome

1 year ago - GlobeNewsWire

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therap...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therap...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therap...

1 year ago - GlobeNewsWire

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company Remain s On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022

1 year ago - GlobeNewsWire

Indaptus Therapeutics to Present at the LD Micro Main Event XV

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micr...

1 year ago - GlobeNewsWire